Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data

European Journal of Clinical Pharmacology

Volumn 54, Issue 2, 1998, Pages 177-183

  Nakasa, H ^a   Nakamura, H ^a   Ono, S ^b   Tsutsui, M ^b   Kiuchi, M ^c   Ohmori, S ^a   Kitada, M ^a  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b Central Laboratory   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

CYP3A4; Zonisamide

Indexed keywords

CAFFEINE; CARBAMAZEPINE; CIMETIDINE; CYCLOSPORIN A; CYTOCHROME P450; DEXTROMETHORPHAN; DIAZEPAM; DIHYDROERGOTAMINE; DRUG METABOLITE; ERYTHROMYCIN; ISOENZYME; ITRACONAZOLE; KETOCONAZOLE; LIDOCAINE; MICONAZOLE; PHENOBARBITAL; PHENOL DERIVATIVE; PHENYTOIN; PRIMIDONE; TERFENADINE; THEOPHYLLINE; TRIAZOLAM; VALPROIC ACID; ZONISAMIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG INTERACTION; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

ANTICONVULSANTS; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROERGOTAMINE; DRUG INTERACTIONS; HUMANS; ISOXAZOLES; ITRACONAZOLE; KETOCONAZOLE; METABOLIC CLEARANCE RATE; MICONAZOLE; TRIAZOLAM;

EID: 0031949650     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050442     Document Type: Article

References (44)

1. Ramsey RE, Wilder BJ, Sackellares JC, Browne T, Guterman A, Barnes D, Mathews J, Berent S, Donofrio PD, Abou-Khalil B, Wagner JG (1984) Multicenter study on the efficacy of zonisamide in the treatment of medically refractory complex partial seizures. Epilepsia 25: 673
2. Sackellares JC, Donofrio PD, Wagner JG, Abou-Khalil B, Berent S, Aasved-Hoyt K (1985) Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia 26: 206-211
3. Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH (1985) Zonisamide in epilepsy: a pilot study. Epilepsia 26: 212-220
4. Ono T, Yagi K, Seino M (1988) Clinical efficacy and safety of a new antiepileptic drug, zonisamide: a multi-institutional phase three study. Clin Psychiatry (Tokyo) 30: 471-482
5. Mimaki T, Sugimoto T, Murata R, Mino M (1990) Therapeutic drug monitoring of serum zonisamide levels in the treatment of patients with refractory seizures. Jpn J Ther Drug Monit 7: 208-214
6. Leppik IE, Willmore LJ, Homan RW, Fromm G, Oommen KJ, Penry JK, Sackellares JC, Smith DB, Lesser RP, Wallace JD, Trudeau JL, Lamoreaux LK, Spenser M (1993) Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 14: 165-173
7. Ito T, Yamaguchi T, Miyazaki H, Sekine Y, Shimizu M, Ishida S, Yagi K, Kakegawa N, Seino M, Wada T (1982) Pharmacokinetic studies of AD-810, a new antiepileptic compound. Arzneim-Forsch Drug Res 32:1581-1586
8. Stiff DD, Zemaitis MA (1990) Metabolism of the anticonvulsant agent zonisamide in the rat. Drug Metab Dispos 18: 888-894
9. Wagner JG, Sackellares JC, Donofrio PD, Berent S, Sakmar E (1984) Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. Ther Drug Monit 6: 277-283
10. Nishiguchi K, Ohnishi N, Iwakawa S, Okumura K, Yagi J, Nakayama S, Takada S, Nakamura H (1990) Pharmacokinetics of zonisamide: a study in pediatric patients with refractory epilepsy. Jpn J Ther Drug Monit 7: 173-178
11. Stiff DD, Robicheau JT, Zemaitis MA (1992) Reductive metabolism of the anticonvulsant agent zonisamide, a 1, 2-ben-zisoxazole derivative. Xenobiotica 22: 1-11
12. Nakasa H, Komiya M, Ohmori S, Kitada M, Rikihisa T, Kanakubo Y (1992) Formation of reductive metabolite, 2-sulfamoylacetylphenol, from zonisamide in rat liver microsomes. Res Commun Chem Pathol Pharmacol 77: 31-41
13. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kitada M (1993) Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. Drug Metab Dispos 21: 777-781
14. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M (1993) Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol 44: 216-221
15. Sugihara K, Kitamura S, Tatsumi K (1996) Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Dispos 24: 199-202
16. Spatzenegger M. Jaeger W (1995) Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27: 397-417
17. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Inter variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and Caucasians. J Pharmacol Exp Ther 270: 414-423
18. Ono S, Tsutsui M, Gonzalez FJ, Satoh T, Masubuchi Y, Horie T, Suzuki T, Narimatsu S (1995) Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus. Pharmacogenetics 5: 97-102
19. Gonzalez FJ, Aoyama T, Gelboin HV (1991) Expression of mammalian cytochrome P450 using vaccinia virus. Methods Enzymol 206: 85-92
20. Nakasa H, Ohmori S, Kitada M (1996) Formation of 2-sulphamoylacetylphenol from zonisamide under aerobic conditions in rat liver microsomes. Xenobiotica 26: 495-501
21. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32: 210-258
22. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275
24. Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378
25. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobio-Dyn 4: 879-885
26. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH (1994) Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem Pharmacol 47: 1969-1979
27. Murray M (1992) P450 enzymes: Inhibition mechanisms, genetics regulation and effects of liver disease. Clin Pharmacokinet 23: 132-146
28. Guengerich FP (1992) Characterization of human cytochrome P450 enzymes. FASEB J 6: 745-748
29. Gorski JC, Jones DR, Wrighton SA, Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes: Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48: 173-182
30. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 264: 10388-10395
31. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, VandenBranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38: 207-213
32. Ojemann LM, Shastri RA, Wilensky AJ, Friel PN, Levy RH, McLean JR, Buchanan RA (1986) Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 8: 293-296
33. Browne TR, Szabo GK, Kres J, Pylio RJ (1986) Drug interaction of zonisamide (CI-912) with phenytoin and carbamazepine. J Clin Pharmacol 26: 555
34. Mimaki T, Sugimoto T, Murata R, Nagai A, Mino M (1992) Zonisamide-phenytoin interaction. Jpn J Ther Drug Monit 9: 49-55
35. Kimura M, Tanaka N, Kimura Y, Miyake K, Kitamura T, Fukuchi H, Harada Y (1992) Factors influencing serum concentration of zonisamide in epileptic patients. Chem Pharm Bull 40: 193-195
36. Riva R, Albani F, Contin M, Baruzzi A (1996) Pharmacokinetic interactions between antiepileptic drugs. Clin Pharmacokinet 31: 470-493
37. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS (1982) Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23: 1-36
38. Beveridge T (1982) Pharmacokinetics and metabolism of cyclospoline A. In: White DJG (ed) Cyclospolin A. Proceedings of the International Conference on Cyclosporin A. Cambridge, UK, pp 35-44
39. Uchida K, Yamaguchi H (1984) Bioassay for miconazole and its levels in human body fluids. Chemotherapy (Tokyo) 32: 541-546
40. Brammer KW, Farrow PR, Faulkner JK (1990) Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Diseases 12 [Suppl 3]: S318-S326
41. Lawless L, DeMonaco H, Muindo L (1982) Protein binding of carbamazepine in epileptic patients. Neurology 32: 415-418
42. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, Cauwenbergh G (1989) The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32 (Suppl 1 ): 67-87
43. Wyss PA, Rosenthaler J, Nüesch E, Aellig WH (1991) Pharmacokinetic investigation of oral and IV dihydroergotamine in healthy subjects. Eur J Clin Pharmacol 41: 597-602
44. Jochemsen R, Wesselman JGJ, Van Boxtel CJ, Hermans J, Breimer DD (1983) Comparative pharmacokineties of brotizolam and triazolam in healthy subjects. Br J Clin Pharmacol 16: 291S-297S